金斯瑞生物科技：24H1点评：生命科学板块展现韧性，CARVYKTI商业化持续放量，前线治疗稳步推进

研究报告 Research Report 12 Aug 2024 金斯瑞生物科技 Genscript Biotech (1548 HK) 24H1 点评：生命科学板块展现韧性，CARVYKTI 商业化持续放量，前线治疗 稳步推进 24H1 Review: Life science shows resilience, commercialization of CARVYKTI gradually heavy volume, and frontline treatment advance smoothly [Table_yemei1] 观点聚焦 Investment Focus | --- | --- | |-----------------------------------------------|---------------------| | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$12.90 | | 目标价 | HK$25.61 | | HTI ESG | 5.0-3.8-4.5 | E ...